Alibaba Health Information Technology Crescita futura
Future criteri di controllo 4/6
Alibaba Health Information Technology prevede che gli utili e i ricavi cresceranno rispettivamente di 21.9% e 9.7% all'anno. Si prevede che l'EPS crescerà di 22.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.3% in 3 anni.
Informazioni chiave
21.9%
Tasso di crescita degli utili
22.2%
Tasso di crescita dell'EPS
| Consumer Retailing crescita degli utili | 28.7% |
| Tasso di crescita dei ricavi | 9.7% |
| Rendimento futuro del capitale proprio | 13.3% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 25 Nov 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Earnings Tell The Story For Alibaba Health Information Technology Limited (HKG:241) As Its Stock Soars 30%
Oct 18
What Does Alibaba Health Information Technology Limited's (HKG:241) Share Price Indicate?
Sep 23Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2027 | 37,997 | 2,603 | 3,032 | 3,435 | 13 |
| 3/31/2026 | 34,190 | 2,131 | 2,399 | 2,333 | 15 |
| 3/31/2025 | 30,976 | 1,667 | 1,679 | 1,695 | 16 |
| 9/30/2024 | 28,344 | 1,207 | 709 | 732 | N/A |
| 6/30/2024 | 27,685 | 1,045 | 883 | 906 | N/A |
| 3/31/2024 | 27,027 | 883 | 1,057 | 1,080 | N/A |
| 12/31/2023 | 27,623 | 851 | 851 | 871 | N/A |
| 9/30/2023 | 28,218 | 817 | 644 | 662 | N/A |
| 6/30/2023 | 27,491 | 675 | 447 | 459 | N/A |
| 3/31/2023 | 26,763 | 536 | 250 | 256 | N/A |
| 12/31/2022 | 24,742 | 332 | 284 | 293 | N/A |
| 9/30/2022 | 22,720 | 128 | 318 | 331 | N/A |
| 6/30/2022 | 21,649 | -69 | 363 | 378 | N/A |
| 3/31/2022 | 20,578 | -266 | 409 | 424 | N/A |
| 12/31/2021 | 19,146 | -216 | 714 | 733 | N/A |
| 9/30/2021 | 17,714 | -167 | 1,018 | 1,041 | N/A |
| 6/30/2021 | 16,616 | 91 | 1,005 | 1,025 | N/A |
| 3/31/2021 | 15,518 | 349 | 992 | 1,009 | N/A |
| 12/31/2020 | 14,080 | 313 | 830 | 842 | N/A |
| 9/30/2020 | 12,642 | 278 | 668 | 674 | N/A |
| 6/30/2020 | 11,119 | 136 | 619 | 629 | N/A |
| 3/31/2020 | 9,596 | -7 | 570 | 584 | N/A |
| 12/31/2019 | 8,465 | -3 | 564 | 577 | N/A |
| 9/30/2019 | 7,334 | 1 | 558 | 570 | N/A |
| 6/30/2019 | 6,215 | -40 | 474 | 483 | N/A |
| 3/31/2019 | 5,096 | -82 | 390 | 396 | N/A |
| 12/31/2018 | 4,264 | -91 | 367 | 373 | N/A |
| 9/30/2018 | 3,432 | -100 | 344 | 349 | N/A |
| 6/30/2018 | 2,937 | -104 | N/A | 139 | N/A |
| 3/31/2018 | 2,443 | -107 | N/A | -70 | N/A |
| 12/31/2017 | 1,876 | -152 | N/A | -157 | N/A |
| 9/30/2017 | 1,310 | -196 | N/A | -244 | N/A |
| 6/30/2017 | 892 | -202 | N/A | -235 | N/A |
| 3/31/2017 | 475 | -208 | N/A | -226 | N/A |
| 12/31/2016 | 285 | -201 | N/A | -186 | N/A |
| 9/30/2016 | 94 | -194 | N/A | -145 | N/A |
| 6/30/2016 | 76 | -193 | N/A | -131 | N/A |
| 3/31/2016 | 57 | -192 | N/A | -117 | N/A |
| 12/31/2015 | 44 | -173 | N/A | -118 | N/A |
| 9/30/2015 | 32 | -154 | N/A | -119 | N/A |
| 6/30/2015 | 31 | -118 | N/A | -87 | N/A |
| 3/31/2015 | 30 | -81 | N/A | -55 | N/A |
| 12/31/2014 | 31 | -60 | N/A | -8 | N/A |
| 9/30/2014 | 31 | -39 | N/A | 38 | N/A |
| 6/30/2014 | 27 | -36 | N/A | 20 | N/A |
| 3/31/2014 | 22 | -31 | N/A | 1 | N/A |
| 12/31/2013 | 16 | -35 | N/A | -26 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di 241 ( 21.9% all'anno) è superiore al tasso di risparmio ( 2.3% ).
Guadagni vs Mercato: Si prevede che gli utili di 241 ( 21.9% all'anno) cresceranno più rapidamente del mercato Hong Kong ( 11.6% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 241 cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di 241 ( 9.7% all'anno) crescerà più rapidamente del mercato Hong Kong ( 7.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 241 ( 9.7% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 241 sarà basso tra 3 anni ( 13.3 %).